Trial Outcomes & Findings for GLP1R Polymorphisms and Response to GLP1 (NCT NCT00588380)

Results Overview

The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

88 participants

Primary outcome timeframe

150 - 180 minutes after GLP-1 infusion

Results posted on

2011-12-19

Participant Flow

Healthy volunteers recruited from Olmsted County, MN.

Participant milestones

Participant milestones
Measure	Overall Study All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.
Overall Study STARTED	88
Overall Study COMPLETED	88
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

GLP1R Polymorphisms and Response to GLP1

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Overall Study n=88 Participants All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.
Age Continuous	26.3 years STANDARD_DEVIATION 5.6 • n=5 Participants
Sex: Female, Male Female	52 Participants n=5 Participants
Sex: Female, Male Male	36 Participants n=5 Participants
Region of Enrollment United States	88 participants n=5 Participants

PRIMARY outcome

Timeframe: 150 - 180 minutes after GLP-1 infusion

Population: all participants completed the study

The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.

Outcome measures

Outcome measures
Measure	All Participants n=88 Participants C-peptide as a marker of insulin secretion
Insulin Secretion at 150-180 Minutes. rs6923761 (1,1) genotype	104 10^-9 min^-1 Standard Error 9
Insulin Secretion at 150-180 Minutes. rs6923761 (1, 2) genotype	94 10^-9 min^-1 Standard Error 11
Insulin Secretion at 150-180 Minutes. rs6923761 (2, 2) genotype	81 10^-9 min^-1 Standard Error 8
Insulin Secretion at 150-180 Minutes. rs3765467 (1,2) genotype	92 10^-9 min^-1 Standard Error 6
Insulin Secretion at 150-180 Minutes. rs3765467 (2,2) genotype	219 10^-9 min^-1 Standard Error 35

SECONDARY outcome

Timeframe: 210 - 240 minutes after GLP-1 infusion

Population: All participants completing the study.

The 240 minute value represents the mean of values obtained at 210, 220, 230, and 240 minutes.

Outcome measures

Outcome measures
Measure	All Participants n=88 Participants C-peptide as a marker of insulin secretion
Insulin Secretion at 210-240 Minutes rs6923761 (1,1) genotype	152 10^-9 min^-1 Standard Error 12
Insulin Secretion at 210-240 Minutes rs6923761 (1,2) genotype	133 10^-9 min^-1 Standard Error 15
Insulin Secretion at 210-240 Minutes rs6923761 (2,2) genotype	112 10^-9 min^-1 Standard Error 10
Insulin Secretion at 210-240 Minutes rs3765467 (1,2) genotype	132 10^-9 min^-1 Standard Error 7
Insulin Secretion at 210-240 Minutes rs3765467 (2,2) genotype	325 10^-9 min^-1 Standard Error 44

Adverse Events

Overall Study

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Adrian Vella

Mayo Clinic

Phone: 507-284-3754

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place